staceywhite, Author at European Medical Journal - Page 9 of 195

Patient and physician perspectives on shared decisions in CML

In this new podcast episode, Lisa Machado, a patient advocate diagnosed with CML in 2008 and clinician and CML expert Jeffrey Lipton, sit…

Physical Function Outcomes in People with Type 2 Diabetes

Physical function decline is an increasingly recognised concern among individuals with long-term conditions such as Type 2 diabetes (T2D)…

Clinical Perspectives on Photosensitivity and Photodiagnostics

Skin photosensitivity is defined as the cutaneous response to UV radiation (UVR) and/or visible light (VL). The Fitzpatrick Skin Phototype…

GLP-1 Receptor Agonists Protect Against Hepatocyte Senescence in MASLD/MASH

Hepatocyte senescence has emerged as a key pathogenic driver in the onset and progression of metabolic dysfunction-associated steatotic…

EASD 2025 Abstract Highlights

The following highlights showcase key research presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2025…

Medical Management of Atopic Dermatitis in Pregnancy and Lactation

Atopic dermatitis (AD) is a common and chronic skin condition that can be significantly impacted by the physiological and immunological…

Nail Psoriasis Treatment: A Narrative Review

Nail psoriasis remains a therapeutic challenge that is insufficiently addressed compared to skin and joint involvement. Treatment choices…

Refractory Ulcerative Lupus Chilblains Treated with Deucravacitinib: A Case Report and Review of the Literature

Cutaneous lupus erythematosus (CLE) encompasses a group of autoimmune skin disorders that may occur independently or in association with…

Nail Lichen Planus: A Comprehensive Review of Clinical Features, Histopathology, and Current Treatment

Nail lichen planus (NLP) is a chronic inflammatory disorder that can lead to irreversible damage, such as pterygium and anonychia. While…

Expert Insights on HER2-Mutant NSCLC

Dr. Joshua Sabari explores recent advances in the treatment of HER2-mutant non-small cell lung cancer, including a newly FDA-approved option…